Related Experiment Videos
Impaired clot retraction in thrombocytopenia due to methyldopa
Southern Medical Journal
|March 1, 1982
Abstract:
We have described a case of thrombocytopenic purpura caused by methyldopa. A methyldopa-dependent antiplatelet antibody as the mechanism of the patient's thrombopenia was suggested by a positive clot retraction inhibition test. This simple in vitro test should be done more often in suspected cases of drug-induced thrombocytopenia.
Insights
Methyldopa can cause thrombocytopenic purpura due to drug-dependent antibodies. A simple clot retraction inhibition test can help diagnose this condition in suspected cases.
Area of Science:
- Hematology
- Pharmacology
- Immunology
Background:
- Drug-induced thrombocytopenia is a significant clinical concern.
- Methyldopa is a medication known to cause adverse hematologic effects.
- Identifying the causative agent and mechanism is crucial for patient management.
Observation:
- A case of thrombocytopenic purpura was observed in a patient treated with methyldopa.
- The patient exhibited a positive clot retraction inhibition test.
- This test suggested the presence of a methyldopa-dependent antiplatelet antibody.
Findings:
- A methyldopa-dependent antiplatelet antibody was identified as the likely mechanism for the patient's thrombocytopenia.
- The clot retraction inhibition test proved to be a valuable diagnostic tool in this case.
- This in vitro assay can detect drug-dependent antibodies affecting platelet function.
Implications:
- The clot retraction inhibition test should be considered for routine use in diagnosing drug-induced thrombocytopenia.
- Early identification of methyldopa-induced immune thrombocytopenia can prevent further complications.
- This case highlights the importance of considering medication side effects in hematologic disorders.